-
1.发明授权sCD40L and placental growth factor (PLGF) as biochemical marker combinations in cardiovascular diseases 有权sCD40L和胎盘生长因子（PLGF）作为心血管疾病的生物化学标记物组合公开(公告)号：US08673581B2
公开(公告)日：2014-03-18
申请号：US13613010
申请日：2012-09-13
CPC分类号： G01N33/6893 , C07K14/70575 , G01N2333/96486 , G01N2800/32
摘要： The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.
摘要翻译： 本发明涉及血管炎症的新型标志物及其组合作为心血管疾病患者的诊断和预后工具。 标记物也作为促进活性成分选择用于治疗这些疾病的工具，最终成为治疗心血管疾病的起点。 此外，本发明涉及创建与动脉硬化进展相关的阴性事件的个体风险特征。
-
2.发明授权sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases 有权sCD40L和胎盘生长因子（PLGF）用作心血管疾病中的生物化学标记物组合公开(公告)号：US08409815B2
公开(公告)日：2013-04-02
申请号：US10534985
申请日：2003-11-10
CPC分类号： G01N33/6893 , C07K14/70575 , G01N2333/96486 , G01N2800/32
摘要： The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.
摘要翻译： 本发明涉及血管炎症的新型标志物及其组合作为心血管疾病患者的诊断和预后工具。 标记物也作为促进活性成分选择用于治疗这些疾病的工具，最终成为治疗心血管疾病的起点。 此外，本发明涉及创建与动脉硬化进展相关的阴性事件的个体风险特征。
-
3.发明申请SCD40L AND PLACENTAL GROWTH FACTOR (PIGF) AS BIOCHEMICAL MARKER COMBINATIONS IN CARDIOVASCULAR DISEASES 有权SCD40L和PLACENTAL GROWTH FACTOR（PIGF）作为生物化学标记物在心血管疾病中的组合公开(公告)号：US20130004487A1
公开(公告)日：2013-01-03
申请号：US13613010
申请日：2012-09-13
IPC分类号： G01N33/53 , A61P9/00 , A61K39/395
CPC分类号： G01N33/6893 , C07K14/70575 , G01N2333/96486 , G01N2800/32
摘要： The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.
摘要翻译： 本发明涉及血管炎症的新型标志物及其组合作为心血管疾病患者的诊断和预后工具。 标记物也作为促进活性成分选择用于治疗这些疾病的工具，最终成为治疗心血管疾病的起点。 此外，本发明涉及创建与动脉硬化进展相关的阴性事件的个体风险特征。
-
4.发明申请公开(公告)号：US20090155827A1
公开(公告)日：2009-06-18
申请号：US11666164
申请日：2005-10-25
CPC分类号： G01N33/74 , G01N33/6893 , G01N2800/324
摘要： The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use.
摘要翻译： 本发明涉及使用离体方法，其包括测定样品中的PlGF和sFlt-1用于具有动脉粥样硬化病因的血管疾病的诊断，风险分层和/或监测，特别是冠状动脉心脏病如不稳定 心绞痛或心肌梗塞，和/或用于估计发生这种疾病的可能性，以及用于鉴定可减轻心血管疾病风险的药物治疗的患者。 在方法（i）参考组的上两个三分位数中的[PlGF =高：sFlt-1 =低]和/或（ii）PlGF浓度的比例和下三分之一中的sFlt-1浓度 的参考集合，和（iii）高于PlGF参考值的PlGF结果，低于sFlt-1参考值的sFlt-1结果表明不良事件的概率升高。 本发明还涉及使用的方法。 本发明还涉及诊断试剂盒及其用途以及测定元件及其用途。
-
5.发明授权In vitro method for the diagnosis of cardiovascular functionality of bone marrow precursor cells (BMPS) and/or blood-derived circulating precursor cells (BDPS) 有权用于诊断骨髓前体细胞（BMPS）和/或血液循环前体细胞（BDPS）的心血管功能的体外方法公开(公告)号：US07919315B2
公开(公告)日：2011-04-05
申请号：US10574380
申请日：2004-10-13
IPC分类号： C12N5/08
CPC分类号： G01N33/56966 , A61K2035/124 , G01N33/5005 , G01N2333/70589 , G01N2333/70596 , G01N2333/71 , G01N2333/755
摘要： The present invention relates to an in vitro method for the analysis of a sample from a mammal in connection with cardiovascular diseases, wherein the method comprises the following steps: a) isolating of bone marrow-precursor cells (BMPs) and/or blood-derived circulating precursor cells (BDPs) by means of cell specific surface markers, and b) detecting the cardiovascular functionality of the isolated BMPs and/or BDPs by means of a suitable migration assay. The method according to the invention can be employed as a kit in the context of the diagnosis and/or the prognosis of cardiovascular diseases, for the monitoring of their therapies and/or for a stratification for a prospective cell therapy with stem- and/or precursor cells in order to increase the perfusion of ischemic tissue or for a regeneration of tissue losses (e.g. heart insufficiency), respectively. In a further aspect, the present invention then relates to an in vitro method for isolating specific bone marrow-precursor cells by means of a suitable migration assay. According to the invention, these BMPs and/or BDPs can be used for the treatment of cardiovascular diseases, selected from the group consisting of stable coronary heart disease, acute coronary syndrome, acute myocardial infarction, chronic ischemic cardiomyopathy (ICMP), dilatative cardiomyopathy (DCM) or other causes for a heart insufficiency.
摘要翻译： 本发明涉及用于分析哺乳动物与心血管疾病相关的样品的体外方法，其中所述方法包括以下步骤：a）分离骨髓前体细胞（BMP）和/或血液来源的 通过细胞特异性表面标志物循环前体细胞（BDP），和b）通过合适的迁移试验检测分离的BMP和/或BDP的心血管功能。 根据本发明的方法可以在心血管疾病的诊断和/或预后的背景下用作试剂盒，用于监测其疗法和/或用于具有茎和/或血管的前瞻性细胞治疗的分层， 为了增加缺血组织的灌注或组织损失（例如心脏功能不全）的再生，分别为前体细胞。 在另一方面，本发明涉及通过合适的迁移试验分离特异性骨髓前体细胞的体外方法。 根据本发明，这些BMP和/或BDP可用于治疗心血管疾病，其选自稳定性冠心病，急性冠状动脉综合征，急性心肌梗死，慢性缺血性心肌病（ICMP），扩张性心肌病 DCM）或心脏功能不全的其他原因。
-
6.发明授权公开(公告)号：US08871731B2
公开(公告)日：2014-10-28
申请号：US13422932
申请日：2012-03-16
IPC分类号： C12N15/11 , A61K31/7125 , C12N15/113 , A61K31/712
CPC分类号： A61K31/712 , A61K31/7125 , C12N15/113 , C12N2310/113
摘要： The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein are methods of treating or preventing cardiac fibrosis and myocardial infarction by administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity.
摘要翻译： 本发明涉及通过调节miR-34家族成员和/或PNUTS的表达或活性来治疗或预防年龄相关性心肌病。 治疗或预防年龄相关性心肌病的方法包括施用miR-34表达或活性的抑制剂或PNUTS表达或活性的激动剂。 本文还提供了通过施用miR-34表达或活性的抑制剂或PNUTS表达或活性的激动剂来治疗或预防心脏纤维化和心肌梗死的方法。
-
公开(公告)号：US08258113B2
公开(公告)日：2012-09-04
申请号：US12739876
申请日：2008-10-30
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/113 , C12N2320/50
摘要： The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein the construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.
摘要翻译： 本发明涉及一种影响细胞中miR-92表达的方法，包括以下步骤：（a）提供细胞; 和（b1）通过将针对miR-92的反义分子引入细胞来促进血管形成或血管修复，或（b2）增加细胞中miR-92的表达， 通过将构建体引入细胞来抑制肿瘤血管发生，其中构建体包含可表达的miR-92序列。 此外，本发明涉及药物组合物，其包含用于降低miR-92的反义分子形式的细胞中的miR-92活性或表达的试剂或用于增加细胞中miR-92表达的试剂 以用于表达miR-92的构建体的形式。
-
8.发明申请公开(公告)号：US20120238619A1
公开(公告)日：2012-09-20
申请号：US13422932
申请日：2012-03-16
IPC分类号： A61K31/7088 , A61P9/10 , A61P9/00
CPC分类号： A61K31/712 , A61K31/7125 , C12N15/113 , C12N2310/113
摘要： The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein are methods of treating or preventing cardiac fibrosis and myocardial infarction by administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity.
摘要翻译： 本发明涉及通过调节miR-34家族成员和/或PNUTS的表达或活性来治疗或预防年龄相关性心肌病。 治疗或预防年龄相关性心肌病的方法包括施用miR-34表达或活性的抑制剂或PNUTS表达或活性的激动剂。 本文还提供了通过施用miR-34表达或活性的抑制剂或PNUTS表达或活性的激动剂来治疗或预防心脏纤维化和心肌梗死的方法。
-
公开(公告)号：US08912158B2
公开(公告)日：2014-12-16
申请号：US13569786
申请日：2012-08-08
IPC分类号： C12N15/11 , C12N15/113 , C07H21/04
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/113 , C12N2320/50
摘要： The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.
摘要翻译： 本发明涉及一种影响细胞中miR-92表达的方法，包括以下步骤：（a）提供细胞; 和（b1）通过将针对miR-92的反义分子引入细胞来促进血管形成或血管修复，或（b2）增加细胞中miR-92的表达， 通过将构建体导入细胞来抑制肿瘤血管生成，其中所述构建体包括可表达的miR-92序列。 此外，本发明涉及药物组合物，其包含用于降低miR-92的反义分子形式的细胞中miR-92活性或表达的试剂或用于增加细胞中miR-92表达的试剂 以用于表达miR-92的构建体的形式。
-
10.发明申请Method for Promoting Angiogenesis, Vascularization, or Vessel Repair or for the Inhibiting Tumor Angiogenesis 有权促进血管生成，血管化或血管修复或抑制肿瘤血管生成的方法公开(公告)号：US20120322856A1
公开(公告)日：2012-12-20
申请号：US13569786
申请日：2012-08-08
IPC分类号： A61K31/7088 , A61P9/10 , A61P25/28 , A61P25/16 , C12N5/078 , A61P29/00 , C12N5/07 , C12N5/0789 , C12N5/077 , C12N5/0793 , C07H21/02 , A61P35/00
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/113 , C12N2320/50
摘要： The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.
摘要翻译： 本发明涉及一种影响细胞中miR-92表达的方法，包括以下步骤：（a）提供细胞; 和（b1）通过将针对miR-92的反义分子引入细胞来促进血管形成或血管修复，或（b2）增加细胞中miR-92的表达， 通过将构建体导入细胞来抑制肿瘤血管生成，其中所述构建体包括可表达的miR-92序列。 此外，本发明涉及药物组合物，其包含用于降低miR-92的反义分子形式的细胞中miR-92活性或表达的试剂或用于增加细胞中miR-92表达的试剂 以用于表达miR-92的构建体的形式。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.026 秒)
